Literature DB >> 19625139

Biologically effective dose-response relationship for breast cancer treated by conservative surgery and postoperative radiotherapy.

George A Plataniotis1, Roger G Dale.   

Abstract

PURPOSE: To find a biologically effective dose (BED) response for adjuvant breast radiotherapy (RT) for initial-stage breast cancer. METHODS AND MATERIALS: Results of randomized trials of RT vs. non-RT were reviewed and the tumor control probability (TCP) after RT was calculated for each of them. Using the linear-quadratic formula and Poisson statistics of cell-kill, the average initial number of clonogens per tumor before RT and the average tumor cell radiosensitivity (alpha-value) were calculated. An alpha/beta ratio of 4 Gy was assumed for these calculations.
RESULTS: A linear regression equation linking BED to TCP was derived: -ln[-ln(TCP)] = -ln(No) + alpha(*) BED = -4.08 + 0.07 (*) BED, suggesting a rather low radiosensitivity of breast cancer cells (alpha = 0.07 Gy(-1)), which probably reflects population heterogeneity. From the linear relationship a sigmoid BED-response curve was constructed.
CONCLUSION: For BED values higher than about 90 Gy(4) the radiation-induced TCP is essentially maximizing at 90-100%. The relationship presented here could be an approximate guide in the design and reporting of clinical trials of adjuvant breast RT.

Entities:  

Mesh:

Year:  2009        PMID: 19625139     DOI: 10.1016/j.ijrobp.2009.05.013

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  Hypofractionated radiotherapy in the treatment of early breast cancer.

Authors:  George Plataniotis
Journal:  World J Radiol       Date:  2010-06-28

3.  Local control following single-dose intraoperative radiotherapy prior to surgical excision of early-stage breast cancer.

Authors:  Randall J Kimple; Nancy Klauber-DeMore; Cherie M Kuzmiak; Dag Pavic; Jun Lian; Chad A Livasy; WingKeung M Chiu; Dominic T Moore; Carolyn I Sartor; David W Ollila
Journal:  Ann Surg Oncol       Date:  2011-04       Impact factor: 5.344

4.  Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity.

Authors:  Letizia Deantonio; Giuseppina Gambaro; Debora Beldì; Laura Masini; Sara Tunesi; Corrado Magnani; Marco Krengli
Journal:  Radiat Oncol       Date:  2010-11-23       Impact factor: 3.481

5.  Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors.

Authors:  Patrizia Ciammella; Ala Podgornii; Maria Galeandro; Renato Micera; Dafne Ramundo; Tamara Palmieri; Elisabetta Cagni; Cinzia Iotti
Journal:  Radiat Oncol       Date:  2014-04-24       Impact factor: 3.481

6.  Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian trial.

Authors:  Grazia Lazzari; Angela Terlizzi; Giuseppina Della Vittoria Scarpati; Francesco Perri; Vincenzo De Chiara; Barbara Turi; Giovanni Silvano
Journal:  Onco Targets Ther       Date:  2017-03-24       Impact factor: 4.147

7.  Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer.

Authors:  Hoon Sik Choi; Hong Seok Jang; Ki Mun Kang; Byung-Ock Choi
Journal:  Radiat Oncol       Date:  2019-06-20       Impact factor: 3.481

8.  Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.

Authors:  Marta Scorsetti; Filippo Alongi; Antonella Fogliata; Sara Pentimalli; Pierina Navarria; Francesca Lobefalo; Carlos Garcia-Etienne; Alessandro Clivio; Luca Cozzi; Pietro Mancosu; Giorgia Nicolini; Eugenio Vanetti; Marco Eboli; Carlo Rossetti; Arianna Rubino; Andrea Sagona; Stefano Arcangeli; Wolfgang Gatzemeier; Giovanna Masci; Rosalba Torrisi; Alberto Testori; Marco Alloisio; Armando Santoro; Corrado Tinterri
Journal:  Radiat Oncol       Date:  2012-08-28       Impact factor: 3.481

9.  Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model.

Authors:  In Ho Song; Youn Noh; Junhye Kwon; Jae Ho Jung; Byung Chul Lee; Kwang Il Kim; Yong Jin Lee; Joo Hyun Kang; Chae Seo Rhee; Chul Hee Lee; Tae Sup Lee; Ik Joon Choi
Journal:  Oncotarget       Date:  2017-09-08

10.  Effect of hypofractionation on the incidental axilla dose during tangential field radiotherapy in breast cancer.

Authors:  Kai J Borm; Markus Oechsner; Mathias Düsberg; Gabriel Buschner; Weber Wolfgang; Stephanie E Combs; Marciana N Duma
Journal:  Strahlenther Onkol       Date:  2020-06-02       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.